New Haven drug developer Achillion Pharmaceuticals has set 2010 base pay and incentives for its senior officers, but delayed a decision on whether they will get 2009 performance bonuses, a regulatory filing shows.
The compensation committee of Achillion’s board of directors approved the salay and stock options to the management team led by CEO Michael Kishbauch, according to a filing with the Securities and Exchange Commission.
Meantime, the committee delayed a decision on the officers’ 2009 bonuses until early next year, the filing said.
Kishbauch will remain the highest-paid executive, drawing a 2010 base salary of $394,800, along with options to buy 142,000 shares at $3.28 a share, records show. Achillion’s stock price as of Dec. 18.
Five other senior officers will draw base pay ranging from $274,800 to $291,500. They also will receive options to buy Achillion shares, the filing said.
The same filing also revealed that Achillion has modified its lease with landlord Winstanley Enterprises on lab and office space at 300 George St. in New Haven.
Â
